Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 6/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | EDNRA | P25101 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31170906 | 0.84 | SLC6A3 (0.48) | SLC6A3SLC6A2SLC6A4KCNH2CYP2D6 | |
| SCHEMBL5829437 | 0.84 | SLC6A3 (0.48) | SLC6A3SLC6A2SLC6A4KCNH2CYP2D6 | |
| SCHEMBL7398621 | 0.82 | ROCK2 (0.51) | SLC6A3SLC6A2SLC6A4KCNH2AOC3 | |
| SCHEMBL8488299 | 0.80 | UTS2R (0.46) | SLC6A3UTS2REDNRA | |
| SCHEMBL6671971 | 0.79 | ALDH1A1 (0.52) | SLC6A3SLC6A2SLC6A4AOC3CYP2D6 | |
| SCHEMBL30992200 | 0.77 | SLC6A3 (0.45) | SLC6A3SLC6A2SLC6A4KCNH2CYP2D6 | |
| SCHEMBL1069341 | 0.76 | LTA4H (0.53) | — | |
| SCHEMBL29941132 | 0.75 | UGT2B7 (0.55) | SLC6A3CYP2D6 | |
| SCHEMBL1579310 | 0.75 | UGT2B7 (0.55) | SLC6A3CYP2D6 | |
| SCHEMBL28595878 | 0.75 | MTNR1A (0.46) | SLC6A3SLC6A2SLC6A4KCNH2UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329298-B2 | Inhibitors of cellular metabolic processes | AGIOS PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2018-03-22 | — | — | US | disclosed |
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329298-B2 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | SLC6A3 3917/4885SLC6A2 3183/4885SLC6A4 3541/4885 |
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | MNAT1, MAT2A, PCK2 | SLC6A3 3917/4885SLC6A2 3183/4885SLC6A4 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.